AuctuCel, a Singapore-based biotechnology company specialising in AI-powered bioprocess technologies, has announced the launch of AuctuPrime, a next-generation chemically defined cell culture medium developed in collaboration with China-based Sperikon.
The formulation is designed to remove dependence on both animal serum and donor-derived human platelet supplements during cell therapy manufacturing.
The launch comes as markets continue to deepen their advanced therapy ecosystems. The Singapore Economic Development Board reported that the country saw a fourfold increase in locally incorporated biotechnology companies since 2015.
In Malaysia, the National Pharmaceutical Regulatory Agency issued updated cell and gene therapy product guidance in September 2025, including revised Good Manufacturing Practice requirements. As more research moves towards clinical translation, the reliability and traceability of manufacturing inputs are receiving greater attention.
AuctuPrime replaces supplements with a fully chemically defined formulation. By giving researchers and manufacturers clearer control over what enters the process, it is intended to provide a more reproducible foundation for scale-up from laboratory research to clinical and commercial manufacturing.
